Lymph directing prodrugs
US-2024050573-A1 · Feb 15, 2024 · US
Extended release dosage forms of metoprolol
US8962016B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8962016-B2 |
| Application number | US-95464410-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 25, 2010 |
| Priority date | Mar 28, 2006 |
| Publication date | Feb 24, 2015 |
| Grant date | Feb 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.
First claim
Opening claim text (preview).
We claim: 1. A water insoluble and water non-swellable inert core for preparation of a solid oral dosage form, wherein the core comprises microcrystalline cellulose spheres coated with one or more water insoluble pharmaceutically acceptable polymers with the proviso that said inert core does not include an active ingredient. 2. The inert core of claim 1 , wherein the water insoluble pharmaceutically acceptable polymer is ethylcellulose. 3. T…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K31/138Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8962016B2 cover?
- The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.
- Who is the assignee on this patent?
- Mandaogade Prashant Manohar, Joshi Venkatesh Madhavacharya, Srivastava Saurabh, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/138. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).